Acorda Therapeutics (ACOR) Rating Reiterated by Cowen

Acorda Therapeutics (NASDAQ:ACOR)‘s stock had its “buy” rating reissued by analysts at Cowen in a research report issued on Friday, November 17th. They currently have a $30.00 price objective on the biopharmaceutical company’s stock. Cowen’s price objective suggests a potential upside of 47.42% from the company’s current price.

A number of other analysts also recently issued reports on ACOR. Stifel Nicolaus reiterated a “buy” rating on shares of Acorda Therapeutics in a report on Friday, July 28th. BidaskClub downgraded shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a report on Tuesday, August 29th. Janney Montgomery Scott reiterated a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a report on Wednesday, August 30th. Finally, Zacks Investment Research downgraded shares of Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 26th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Acorda Therapeutics currently has a consensus rating of “Hold” and an average price target of $21.47.

Acorda Therapeutics (NASDAQ:ACOR) traded down $0.10 on Friday, hitting $20.35. 372,100 shares of the company were exchanged, compared to its average volume of 932,747. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77. Acorda Therapeutics has a 52 week low of $13.60 and a 52 week high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.26). The company had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The business’s revenue was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.04) earnings per share. equities analysts expect that Acorda Therapeutics will post -0.07 earnings per share for the current year.

In related news, insider Burkhard Blank sold 11,050 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.53, for a total transaction of $226,856.50. Following the transaction, the insider now directly owns 33,150 shares in the company, valued at approximately $680,569.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.90% of the company’s stock.

A number of large investors have recently modified their holdings of ACOR. State Street Corp grew its holdings in Acorda Therapeutics by 52.4% during the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock valued at $48,783,000 after purchasing an additional 851,290 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Acorda Therapeutics by 29.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock valued at $46,745,000 after purchasing an additional 541,418 shares during the last quarter. RA Capital Management LLC grew its holdings in Acorda Therapeutics by 83.8% during the 2nd quarter. RA Capital Management LLC now owns 900,259 shares of the biopharmaceutical company’s stock valued at $17,735,000 after purchasing an additional 410,431 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Acorda Therapeutics by 306.8% during the 2nd quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock valued at $10,538,000 after purchasing an additional 403,467 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Acorda Therapeutics by 65.2% during the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock valued at $17,690,000 after purchasing an additional 354,304 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://ledgergazette.com/2017/12/07/cowen-and-company-reaffirms-buy-rating-for-acorda-therapeutics-inc-acor.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply